ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 028,15
0,39%
Dow Jones
38 852,27
0,46%
DAX
18 233,25
0,34%
Brent Oil
83,255
-0,26%
Bitcoin
63 607,53
0,70%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ChromaDex Corporation (CDXC)

  7. ChromaDex Corporation (CDXC) Actualités

CDXC ChromaDex Corporation

3,80
0,00 (0,00%)
07 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
ChromaDex Corporation CDXC NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 3,80 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
3,80
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202414:32BWChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR),..
25/4/202414:34BWChromaDex Announces Nationwide Launch of Tru Niagen® at The..
24/4/202414:34BWChromaDex to Report First Quarter 2024 Financial Results on..
23/4/202414:32BWChromaDex Announces Inaugural Major Grocery Debut of Tru..
26/3/202413:32BWChromaDex Announces Tru Niagen® is Now Third-Party Verified..
06/3/202422:04BWChromaDex Corporation Reports Fourth Quarter and Fiscal Year..
06/3/202422:02EDGAR2Form 8-K - Current report
06/3/202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
24/2/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/2/202402:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202414:32BWChromaDex to Report Fourth Quarter 2023 Financial Results on..
05/2/202414:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
26/1/202422:08BWChromaDex to Present at the Lytham Partners 2024 Investor..
20/12/202315:04BWChromaDex Supports the US Military with its Industry Leading..
13/12/202322:00EDGAR2Form 8-K - Current report
12/12/202316:30PRNUSNeurohacker Collective and ChromaDex Partner to Optimize..
04/12/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202314:34BWA Milestone Phase I Randomized, Double-Blind Clinical Trial..
15/11/202314:32BWNewly Published Phase II Clinical Study Demonstrates that..
09/11/202314:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
08/11/202322:02EDGAR2Form 8-K - Current report
08/11/202322:02BWChromaDex Corporation Reports Third Quarter 2023 Financial..
08/11/202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202313:34BWChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg..
31/10/202313:34BWChromaDex to Report Third Quarter 2023 Financial Results on..
26/10/202314:32BWChromaDex and Zesty Paws® Crack the Code on Cellular Health..
02/10/202314:32BWA Milestone Clinical Study Reveals that Elevating..
07/9/202312:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202312:20EDGAR2Form SC 13D/A - General statement of acquisition of..
24/8/202314:32BWPreclinical Study Builds on Growing Body of Evidence..
16/8/202303:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202322:02EDGAR2Form 8-K - Current report
09/8/202322:02BWChromaDex Corporation Reports Second Quarter 2023 Financial..
09/8/202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202314:34BWChromaDex Launches Tru Niagen® with iHerb, the World’s..
07/8/202314:32BWChromaDex to Participate in Renmark’s Virtual Non-Deal..
02/8/202314:02BWChromaDex to Report Second Quarter 2023 Financial Results on..
18/7/202314:32BWFindings from Published Abstracts Showcase the Importance of..
06/7/202322:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/7/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
16/6/202314:32BWChromaDex, a Global Authority on Nicotinamide Adenine..
30/5/202314:34BWChromaDex to Participate in the LD Micro Invitational XIII
11/5/202314:34BWChromaDex to Present at the Lytham Partners Spring 2023..
10/5/202322:02BWChromaDex Corporation Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
CDXC
ChromaDex
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés